香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何 部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 Town Health International Medical Group Limited 康健國際醫療集團有限公司 司） （於開曼群島註冊成立及於百慕達存續之有限公 （股份代 號：3886） (1)有關收購目標集團的溢利保證的最新消息；及 (2)有關二零二四年年報的補充公告 (1) 溢利保證的最新消息 茲提述康健國際醫療集團有限公司（「本公司」，連同其附屬公司「本集團」）日 期為二零二二年七月十一日、二零二二年八月十五日、二零二二年八月二十六 日、二零二四年四月十九日及二零二四年七月二十三日之公告（統稱「該等公 告」），內容有關收購Central Medical Holdings Limited及其附屬公司（「目標集 團」）之全部權益及相關溢利保證。除非另有規定，本公告所用詞彙具有於該等 公告所賦予的相同涵義。 1 本公司謹此通知股東，就截至二零二三年三月三十一日止財政年度溢利保證的 索賠金額對答 ...

由未经审核综合亏损扭亏为盈至未经审核综合溢利乃主要由于以下各项的综合影响：截至2025年6月30 日止6个月取得的本集团投资物业的公平值亏损较截至2024年6月30日止6个月减少;截至2025年6月30日 止6个月就本集团于联营公司的权益并无取得减值亏损，而截至2024年6月30日止6个月就本集团于联营 公司的权益则取得减值亏损;截至2025年6月30日止6个月取得本集团应占联营公司溢利，而截至2024年6 月30日止6个月则取得应占联营公司亏损;及截至2025年6月30日止6个月取得的本集团毛利较截至2024年 6月30日止6个月减少。 康健国际医疗(03886)发布公告，预期本集团于截至2025年6月30日止6个月将取得约2520万港元至3960 万港元的未经审核综合溢利，当中包括约910万港元至1430万港元的未经审核股东应占综合溢利，而于 截至2024年6月30日止6个月，则取得未经审核综合亏损约2850万港元，当中包括未经审核股东应占综合 亏损约4770万港元。 ...

Core Viewpoint - 康健国际医疗 (03886) expects to achieve an unaudited consolidated profit of approximately HKD 25.2 million to HKD 39.6 million for the six months ending June 30, 2025, a significant turnaround from an unaudited consolidated loss of approximately HKD 28.5 million for the six months ending June 30, 2024 [1] Financial Performance - The expected unaudited profit includes an estimated unaudited profit attributable to shareholders of approximately HKD 9.1 million to HKD 14.3 million [1] - The previous period (ending June 30, 2024) recorded an unaudited loss attributable to shareholders of approximately HKD 47.7 million [1] Factors Influencing Performance - The turnaround from loss to profit is primarily due to several factors: - The fair value loss of the group's investment properties for the six months ending June 30, 2025, decreased compared to the same period in 2024 [1] - No impairment loss was recorded for the group's interests in joint ventures for the six months ending June 30, 2025, whereas an impairment loss was recorded for the same period in 2024 [1] - The group recognized a profit from its share of joint ventures for the six months ending June 30, 2025, compared to a loss for the same period in 2024 [1] - The group's gross profit for the six months ending June 30, 2025, decreased compared to the same period in 2024 [1]

Core Viewpoint - 康健国际医疗 (03886.HK) expects to report an unaudited consolidated profit ranging from approximately HKD 25.2 million to HKD 39.6 million for the six months ending June 30, 2025, compared to an unaudited consolidated loss of approximately HKD 28.5 million in the same period last year [1] Group 1: Financial Performance - The expected unaudited profit includes an estimated unaudited profit attributable to shareholders ranging from approximately HKD 9.1 million to HKD 14.3 million [1] - The turnaround from an unaudited consolidated loss to profit is primarily due to several factors, including a reduction in fair value losses on investment properties compared to the same period last year [1] - The company did not record impairment losses on its interests in associates during the period, whereas it recorded such losses in the same period last year [1] - The group recorded profits from its share of associates during the period, in contrast to losses in the same period last year [1] - The group's gross profit decreased compared to the same period last year [1] Group 2: Operating Profit - Excluding the "other income and losses net" shown in the unaudited condensed consolidated income statement, the group expects to report an unaudited operating profit ranging from approximately HKD 27.1 million to HKD 42.6 million [2] - This includes an estimated unaudited operating profit attributable to shareholders ranging from approximately HKD 11 million to HKD 17.3 million [2] - The group is still assessing and valuing its related assets, and further adjustments to the asset amounts may occur once the final results of the assessments and valuations are obtained [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部 分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 Town Health International Medical Group Limited 康健國際醫療集團有限公司 （於開曼群島註冊成立及於百慕達存續之有限公 司） （股份代 號：3886） 正面盈利預告 康健國際醫療集團有限公司（「本公司」，連同其附屬公司統稱「本集團」）乃根據香港 法例第571章證券及期貨條例第XIVA部項下之內幕消息條文及香港聯合交易所有限 公司證券上市規則第13.09(2)條發出本公告。 (i) 截至二零二五年六月三十日止六個月錄得的本集團投資物業的公平值虧損較 截至二零二四年六月三十日止六個月減少； 1 倘排除於未經審核簡明綜合損益表中所示的「其他收益及虧損淨額」後，本集團預期 截至二零二五年六月三十日止六個月，就其業務經營將錄得介乎約27,100,000港元 至42,600,000港元之未經審核經營溢利，當中包括介乎約11,000,000港元至17,300,000 港元之 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 康健國際醫療集團有限公司 呈交日期: 2025年8月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 03886 | 說明 | 康健國際醫療 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 30,000,000,000 | HKD | | 0.01 HKD | | 300,000,000 | | 增加 / 減少 (-) | | | 0 | | | HKD | | 0 | | 本月底結存 | | | 30,000,000,000 | HKD | | 0.01 HKD | | 300,000,000 | | 2. 股份分類 | ...

Summary of LME Non-Ferrous Metal Inventory Report Core Viewpoint - The report provides an update on the inventory levels of various non-ferrous metals at the London Metal Exchange (LME), indicating changes in stock levels for copper, aluminum, nickel, zinc, lead, and tin. Group 1: Inventory Changes - Copper inventory stands at 91,250 tons, with an increase of 625 tons [1] - Aluminum inventory is at 348,625 tons, reflecting an increase of 2,875 tons [1] - Nickel inventory is recorded at 203,886 tons, showing a decrease of 120 tons [1] - Zinc inventory totals 114,900 tons, with a reduction of 2,575 tons [1] - Lead inventory is at 270,075 tons, down by 1,850 tons [1] - Tin inventory is at 2,220 tons, with an increase of 45 tons [1]

Company Overview - The group celebrated its 35th anniversary in 2024, becoming one of the largest and oldest listed healthcare groups in Hong Kong[8]. - The group operates 435 medical service points, providing a wide range of services including general practice, specialist, and dental care[10]. - The group plans to open a new cardiology center in Tuen Mun in Q1 2025 to enhance its cardiology services[12]. - Approximately HKD 18 million was invested in acquiring a retail space in Rainbow Plaza to establish a new medical center[12]. - The group is actively participating in government-funded primary healthcare initiatives and promoting the development of primary healthcare in Hong Kong[10]. Financial Performance - The group recorded a loss of approximately HKD 158.2 million for the year, compared to a loss of HKD 159.1 million in the previous year[21]. - The operating profit for the year was approximately HKD 70.9 million, down from HKD 86.4 million in the previous year[21]. - Gross profit decreased to approximately HKD 487.4 million from HKD 501.9 million, primarily due to a reduction in gross margin in certain mainland China businesses[23]. - The group's medical services revenue in Hong Kong was approximately HKD 787,053,000, representing an increase from HKD 770,996,000 in 2023, accounting for about 42.92% of total revenue[31]. - The group's Hong Kong medical network management revenue for 2024 is approximately HKD 489.35 million, accounting for about 26.69% of total revenue, a slight decrease from 27.18% in 2023[38]. Operational Developments - The group has implemented cost-reduction measures to maintain its competitive edge in the increasingly competitive local healthcare market[10]. - The group has introduced a multi-brand strategy for its specialist services, with continuous development in cardiology and orthopedics[12]. - The group is renovating its Shatin Hilton Center and plans to reopen three general practice centers and one pediatric center in Q1 2025[12]. - The group is expanding its health management services in Guangdong, Shenzhen, and Jinan, focusing on personalized health management projects[16]. - The group aims to integrate healthcare resources across Hong Kong and mainland China to meet the health needs of over 86 million residents in the Greater Bay Area[17]. Certifications and Quality Assurance - Vio has become the first and only medical network in Hong Kong to hold both ISO 9001:2015 and ISO 27001:2022 certifications[13]. - The new corporate logo and branding reflect the group's commitment to quality healthcare services and a refreshed corporate image[9]. - The group emphasizes the importance of long-term relationships with clients and customizes healthcare plans to meet diverse corporate client needs[13]. Challenges and Market Conditions - The group recognizes the challenge posed by the increasing trend of Hong Kong residents seeking medical services in mainland China due to shorter wait times and lower costs[10]. - The group is implementing cost control measures and improving operational efficiency to enhance overall competitiveness amid challenging market conditions[27]. - The group maintains a cautiously optimistic outlook for the private healthcare market in Hong Kong and mainland China, despite challenges such as rising costs and geopolitical tensions[52]. Employee and Management - The total employee cost for the year was approximately HKD 743,697,000, compared to HKD 740,650,000 in 2023, with a workforce of 1,441 employees[68]. - The company has a total of 1,279 employees as of December 31, 2024, with 89% being full-time and 11% part-time[169]. - Employee turnover rate during the reporting period is 21%, with 267 employees leaving the company[172]. - The company provides competitive salaries, promotion opportunities, and benefits to attract and retain talent, including mandatory provident fund and medical insurance[176]. Environmental, Social, and Governance (ESG) Initiatives - The board conducts annual reviews of the group's environmental, social, and governance (ESG) performance and identifies related risks[102]. - The group has set environmental protection goals, including waste reduction and energy conservation, to significantly improve environmental performance and promote business growth[103]. - The company has committed to improving its environmental, social, and governance (ESG) management through ongoing communication with stakeholders[113]. - The company actively engages with stakeholders, collecting constructive feedback through regular meetings and performance reviews to enhance business performance[109]. Health and Safety - The company emphasizes the importance of employee health and safety, adhering to local laws and regulations[181]. - The company reported zero fatal work accidents over the past three years, maintaining a fatal accident rate of 0%[183]. - There were 3 cases of work injuries resulting in more than 3 days lost during the reporting period, a decrease from 7 cases in the previous year[183]. Community Engagement - The company has established partnerships with local charities to support community service and youth development initiatives[108]. - The company has identified five major areas of importance related to social issues and healthcare practices, ensuring compliance with legal requirements[113].

Financial Performance - The group recorded revenue of approximately HKD 1,833,795,000 for the year, a slight increase from HKD 1,833,038,000 in the previous year, representing a growth of 0.04%[3] - The net loss for the group was approximately HKD 158,207,000, compared to a net loss of HKD 159,089,000 in the previous year, indicating a reduction in loss of 0.55%[3] - The total comprehensive loss attributable to the company's owners was HKD 257,087,000, compared to HKD 231,360,000 in the previous year, representing an increase in loss of 11.09%[5] - The basic and diluted loss per share increased to HKD 3.01 from HKD 2.87, indicating a worsening of loss per share by 4.87%[5] - The company reported a pre-tax loss of HKD 120,863 for the year, reflecting challenges in various segments[25] - The company reported a net loss attributable to shareholders of 203,703,000 HKD for 2024, compared to a loss of 194,210,000 HKD in 2023, indicating an increase in losses of 4.8%[34] Assets and Liabilities - The group's total assets decreased to approximately HKD 3,380,347,000 from HKD 3,618,746,000, reflecting a decline of 6.58%[3] - The group's non-current assets decreased to HKD 2,232,058,000 from HKD 2,558,678,000, a decline of 12.76%[6] - The total liabilities decreased slightly to HKD 594,198,000 from HKD 597,372,000, a reduction of 0.46%[7] - The group's bank borrowings decreased to HKD 80,683,000 from HKD 87,563,000, with non-current liabilities amounting to HKD 63,089,000[42] - The group's expected credit loss provision for other receivables was approximately HKD 6,704,000, compared to zero in the previous year[43] - The company's receivables and other receivables totaled 462,852,000 HKD in 2024, down from 511,071,000 HKD in 2023, reflecting a decrease of 9.4%[38] Revenue Breakdown - Revenue from Hong Kong medical services reached HKD 787,053,000, an increase from HKD 770,996,000 in the previous year, representing a growth of 2.9%[16] - Revenue from mainland China hospital management and medical services was HKD 546,615,000, down from HKD 552,795,000, reflecting a decrease of 1.1%[16] - The company reported a total service income of HKD 1,819,007,000 under the gross basis, compared to HKD 1,817,027,000 in the previous year, showing a marginal increase of 0.1%[18] - Revenue from Hong Kong was HKD 1,287,180, up from HKD 1,280,243 in the previous year, while revenue from other regions in China decreased to HKD 546,615 from HKD 552,795[26] Dividends and Shareholder Returns - The group proposed a final dividend of HKD 0.12 per share, unchanged from the previous year[2] - The company declared a final dividend of 0.12 HKD per share for 2024, consistent with the dividend declared for 2023, totaling approximately 8,128,000 HKD[33] Operational Developments - The company has established a comprehensive service system covering primary to high-end cross-specialty medical services, enhancing its competitive advantage and market share[61] - The company has expanded its health management operations in mainland China, responding to the rising demand for healthcare due to an aging population and increasing chronic disease rates[55] - The company has implemented cost control measures and improved operational efficiency to enhance overall competitiveness amid economic uncertainties and industry challenges[54] - The group is actively seeking potential acquisition opportunities in Hong Kong and mainland China to expand its operational scale[85] Employee and Cost Management - The total employee cost for the year was approximately HKD 743,697,000, compared to HKD 740,650,000 in 2023, with 1,441 employees hired, an increase from 1,399 in the previous year[91] - The company reported a total employee cost of 743,697,000 HKD for 2024, a marginal increase from 740,650,000 HKD in 2023[32] Future Outlook and Strategic Initiatives - The company plans to leverage its medical resources to support the Hong Kong government's primary healthcare initiatives, enhancing collaboration on community health programs[78] - The group plans to open three general medical centers and one pediatric center in Sha Tin by Q1 2025, enhancing primary and multi-specialty services[80] - The group aims to strengthen its specialist brand presence in densely populated communities, with a new cardiology center opening in Tuen Mun by Q1 2025[80] - The group will establish a medical advisory committee to ensure compliance with legal and social needs while enhancing the quality of medical services[80] Market Position and Customer Engagement - Major customer A accounted for 21% of total revenue in 2024, down from 22% in 2023, indicating a slight diversification in customer base[28] - The company has developed a strong customer base in health management, demonstrating the effectiveness of its forward-looking operational strategies in mainland China[55] - TBMG has built a complete customer database, utilizing big data to enhance customer satisfaction and retention through personalized services[76] Compliance and Governance - The group has received approval from its auditor for the consolidated financial statements for the year, confirming the accuracy of the reported figures[107] - The executive directors include the chairman and CEO, along with several other key members, indicating a stable leadership structure[110]

Financial Performance - The group recorded revenue of approximately HKD 914,280,000, a slight decrease from HKD 916,833,000 in the previous year[9]. - The group reported a net loss of approximately HKD 28,542,000, compared to a net profit of HKD 38,683,000 in the previous year[9]. - For the first half of 2024, the group's unaudited operating profit was approximately HKD 41,030,000, compared to HKD 37,464,000 in 2023, indicating a positive growth trend despite external challenges[16]. - The group recorded an unaudited loss of approximately HKD 28,542,000 for the first half of 2024, a significant decline from a profit of HKD 38,683,000 in the same period of 2023[16]. - The company reported a total comprehensive loss of HKD 96,094,000 for the six months ended June 30, 2024, compared to a loss of HKD 50,468,000 in the same period of 2023, representing an increase in loss of 90.5%[105]. - The group reported a loss attributable to shareholders of HKD 47,676,000 for the six months ended June 30, 2024, compared to a profit of HKD 21,061,000 in 2023[145]. Assets and Liabilities - The group's current assets net value was approximately HKD 1,360,735,000, up from HKD 1,344,516,000 as of December 31, 2023[9]. - The total net assets of the group are approximately HKD 3,524,725,000 as of June 30, 2024[76]. - The total liabilities decreased to HKD 489,309,000 from HKD 597,372,000, indicating a decrease of 18.1%[107]. - The company's equity attributable to owners decreased to HKD 3,137,907,000 from HKD 3,242,129,000, a decline of 3.2%[107]. - The company reported a liability portion of convertible bonds amounting to HKD 109,633,000 as of June 30, 2024, down from HKD 223,756,000 at the end of 2023, reflecting a significant reduction[167]. Revenue Breakdown - Medical service revenue for the first half of 2024 was approximately HKD 394,462,000, representing an increase from HKD 389,333,000 in 2023, and accounting for 43.14% of total revenue[18]. - Revenue from Hong Kong medical services, including medical and dental services, was HKD 394,462,000, up from HKD 389,333,000 year-on-year[125]. - Revenue from dental services increased to HKD 33,558,000, compared to HKD 29,757,000 in the previous year, reflecting an increase of approximately 12.0%[125]. - Revenue from the Hong Kong medical network management business was HKD 250,043,000, up from HKD 238,105,000, indicating a growth of about 5.0%[125]. - Revenue from hospital management and medical services in mainland China was HKD 264,377,000, down from HKD 283,378,000, representing a decline of approximately 6.7%[125]. Operational Highlights - The group operates a network of 422 medical service points, including 239 general practice points and 68 specialist points, with a total of 798 medical professionals providing services[17]. - The group continues to support government primary healthcare initiatives, participating in various public-private collaboration health programs[20]. - The high-end integrated specialty brand, 中卓醫務, has expanded its services to include 23 types of specialty medical and clinical services, enhancing its competitive advantage[23]. - The internet hospital managed by Nanyang Xiangrui served over 850,000 patients since its launch in March 2022, with 44 departments and around 400 doctors providing various online services[29]. - The newly opened sports rehabilitation center in Nanyang City is the first of its kind, offering personalized health management plans across nine areas, targeting various age groups and health conditions[32]. Financial Management - The company has approximately HKD 300,000,000 in undrawn bank financing available as of June 30, 2024, maintaining financial flexibility[48]. - The company has pledged assets valued at approximately HKD 300,802,000 as of June 30, 2024, for mortgage loans and general bank financing[57]. - The company plans to utilize the remaining net proceeds from the first tranche for acquisitions and investments in healthcare-related businesses by the end of 2026[67]. - The company has initiated legal proceedings against the defendants for the claim amount of HKD 97,956,690 due to non-fulfillment of profit guarantees[61]. Market and Competition - The group is facing increased competition in the non-emergency healthcare services sector due to rising cross-border medical consumption trends[16]. - The group continues to expand its health management services in Guangdong, Shenzhen, and Jinan, with a focus on local healthcare needs and strategic partnerships with nearby hospitals[33]. - Vio's organic growth was supported by a highly experienced management team and efficient IT systems, despite challenges such as a declining workforce and rising employee costs due to population outflow in Hong Kong[26]. Corporate Governance - The company continues to adhere to the corporate governance standards as outlined in the listing rules[94]. - The audit committee reviewed the financial statements for compliance with accounting principles and internal controls[95]. - The board believes that having the same person serve as both chairman and CEO will ensure consistent leadership and enhance operational efficiency[90].